tbuckley/cabot-search huggingface dataset:
Abstract 1638: Targeted Deletion Of Endothelial Lipase Protects Against Allergic Asthma Through Raising Plasma HDL Level And Attenuating Eosinophil Infiltration
Authors: Tatsuro Ishida, Hiroshi Otera, Tomoyuki Yasuda, Yoshihiro Nishimura, Ken-ichi Hirata
Journal: Circulation (2008)

Background: High-density lipoprotein cholesterol (HDL-C) has a variety of anti-inflammatory properties. Endothelial lipase (EL) is a novel phospholipase and a physiological regulator of plasma HDL-C levels. In this study, we investigated the role of HDL-C in allergic inflammation in the lung using EL-deficient (EL-KO) mice that have the high level of plasma HDL-C. Methods and Results: EL-KO and wild-type control mice were sensitized and challenged with ovalbumin to induce allergic asthma. In wild-type mice, EL was expressed in epithelial cells, alveolar type II cells, as well as endothelial cells in the lung, and the expression is upregulated during the ovalbumin-induced inflammation. The number of eosinophils in bronchoalveolar lavage and the expression of vascular cell adhesion molecule-1 (VCAM-1) were lower in EL-KO than in control mice, concomitant with attenuated hypercontraction of the airway smooth muscle cells. HDL reduced the cytokine-induced VCAM-1 expression in cultured endothelial cells. These...
Lipopolysaccharide Activates Caspase-1 (Interleukin-1–Converting Enzyme) in Cultured Monocytic and Endothelial Cells
Authors: Ralf R. Schumann, Claus Belka, Dirk Reuter, Norbert Lamping, Carsten J. Kirschning, Joerg R. Weber, Dagmar Pfeil
Journal: Blood (1998)
Genetic and Pharmacological Analyses of Syk Function in IIbβ3 Signaling in Platelets
Authors: Debbie A. Law, Lisa Nannizzi-Alaimo, Kathleen Ministri, Paul E. Hughes, Jane Forsyth, Martin Turner, Sanford J. Shattil, Mark H. Ginsberg, Victor L.J. Tybulewicz, David R. Phillips
Journal: Blood (1999)
Fortnightly Review: Neonatal screening for sickle cell disorders: what about the carrier infants?
Authors: L. Laird, C. Dezateux, E. N Anionwu
Journal: BMJ (1996)

<h3>Summary points</h3> Neonatal screening for sickle cell disorders detects between 17 and 100 carrier infants for each child detected as having sickle cell disorder Information on neonatal carrier status is an unavoidable outcome of the neonatal screening process Withholding information from parents is not justified Further research is needed to evaluate the benefits and risks of this information and the effectiveness of different policies for follow up This is relevant to future developments in molecular genetics, which may place health
Abstract 19159: Apob48 as a Marker of Atherosclerosis in Patients with Familial Lipid Disorders, Type 2 Diabetes Mellitus and Coronary Artery Disease
Authors: A Alipour, P Valdivielso, Jwf Elte, JW Janssen, J Rioja, TL Njo, P Gonzáalez-Santos, AP Rietveld, M Castro Cabezas
Journal: Circulation (2010)

Objective: Postprandial accumulation of atherogenic remnants has been described in patients with type 2 diabetes mellitus (T2DM), familial combined hyperlipidemia (FCH), familial hypercholesterolem...
Naloxone administration in obsessive-compulsive disorder: report of two cases
Authors: T R Insel, D Pickar
Journal: American Journal of Psychiatry (1983)

Two patients with obsessive-compulsive disorder experienced an exacerbation of chronic obsessional doubt after double-blind, placebo-controlled administration of naloxone. Endogenous opiates may be involved in the pathogenesis of this symptom.
Dietetica.
Authors: A Furlan
Journal: JAMA (1930)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Listeriosis outbreak caused by Latin-style fresh cheese, Bizkaia, Spain, August 2012
Authors: V de Castro, J M Escudero, J L Rodriguez, N Muniozguren, J Uribarri, D Saez, J Vazquez
Journal: Eurosurveillance (2012)

Two cases of laboratory-confirmed listeriosis were detected in Bizkaia, Spain, at the end of August. The epidemiological investigation indicated that these two cases were associated with the consumption of Latin-style fresh cheese made from pasteurised milk in Portugal. Different batches of the same cheese were analysed and confirmed as contaminated with Listeria monocytogenes. The product was withdrawn from the market and the population was advised not to consume this kind of cheese.
Abstract 5605: Real World Comparison of Long Term Mortality after Primary Percutanous Coronary Intervention (PPCI) versus Fibrinolysis for Acute St Elevation Myocardial Infarction: Initial Experience from the 24 Hour PPCI Program in Nova Scotia
Authors: Boniface Chan, Helen Curran, Michael P Love, Stephen Fort
Journal: Circulation (2008)

Background Randomized controlled trials indicate that acute ST elevation myocardial infarction (STEMI) patients have better clinical outcomes if rapid, complete and stable coronary artery patency can be achieved. The Queen Elizabeth II Health Sciences Center in Halifax, Nova Scotia (QEIIHSC) commenced a 24 hour PPCI program in November 2005. This real world study compares 2 year mortality in STEMI patients treated by PPCI versus patients treated by fibrinolysis with provisional rescue PCI within Nova Scotia, Canada. Methods This was a single center retrospective cohort study. All consecutive Nova Scotia, fibrinolytic and PPCI eligible STEMI patients presenting within 12 hours of symptom onset between July 1 st 2005 and June 30 th 2006 treated by PPCI at the QEIIHSC or fibrinolyis outside the QEIIHSC were included. The outcome measure was all cause mortality censored on June 30 th 2007. The crude and independent association between PPCI versus fibrinolysis on mortality was estimated using a Cox regression model. Results Data for 423 eligible patients (100% of cohort) comprised of 359/423 (85%) patients treated with fibrinolytics and 64/359 (18%) treated by PPCI were analyzed. The median follow-up was 1.4 years. The median (Q25 to Q75) door to needle times in the fibrinolytic group and corresponding door to balloon times in the PPCI group were: 0.5 (.3 to .9) and 1.5 (1.1 to 1.9) hours respectively. PPCI was associated with a consistent trend toward lower mortality versus fibrinolysis during hospitalization: 2/64 (3.1%) vs. 29/359 (8.1%), P=0.16 and at 30 days 2/64 (3.1%) vs. 32/359 (15%), P=0.12. This association was significant at 1 and 2 year follow-up: 2/64 (3.1%) vs. 41/359 (11%), P=0.043 and 2/64 (3.1%) vs. 45/359 (12%), P=0.027 respectively. This corresponded with an independent HR for 2 year mortality of: 0.1 (.01 to 0.8), p=0.03. Conclusion Initial data from the PPCI program at the QEIIHSC in Halifax, Nova Scotia indicates that PPCI was associated significant reductions in mortality versus fibrinolysis for real world patients presenting with STEMI. This mortality reduction was achieved in the early pilot phase of a PPCI program with evolving door to balloon timelines versus an established fibrinolytic program with acceptable door to needle timelines.
Abstract 312: Akt1-Mediated Muscle Growth Will Regress Adiposity and Insulin Resistance in Obese Mice
Authors: Yasuhiro Izumiya, Nathan K LeBrasseur, Carl Morris, Teresa Hopkins, Kaori Sato, Jason Viereck, Ling Zeng, Rei Shibata, Noriyuki Ouchi, Ichiro Shiojima, James A Hamilton, Kenneth Walsh
Journal: Circulation (2006)

Obesity is the most common risk factor for cardiovascular diseases. Although it is known that increasing skeletal muscle activity can reduce obesity and improve obesity-related diseases, mouse models that can assess the molecular relationships between muscle growth and obesity are lacking. We have generated a skeletal muscle-specific, conditional transgenic (TG) mouse that can induce the growth of functional skeletal muscle by switching Akt1 signaling on or off and assessed the hypothesis that robust skeletal muscle growth can reverse obesity and insulin resistance in diet-induced obese mice. Activation of Akt1 signaling for 2 weeks led to an increase in muscle mass (238.0±6.9 vs. 170.6±4.9 mg, gastrocnemius muscle weight, p<0.01). Akt1-induced muscle hypertrophy led to higher peak grip force compared with control muscle (104.7±3.7 vs. 69.8±0.8 g, p<0.05). Under conditions of repressed Akt1 expression, mice were fed high fat/sucrose diet to induce obesity. Although there was no difference in daily food intake, activation of Akt1 signaling in skeletal muscle of obese mice dramatically reduced fat mass calculated by MRI measurements (3.9±0.7 vs. 8.4±0.7 cm3, p<0.01). TG mice showed increased oxygen consumption ratio measured by indirect colorimeter (2887±66 vs. 2615±62ml/kg/min, p<0.01), in spite of decrease in ambulatory activity levels (20788±2911 vs. 34557±3932 beam brakes/day, p<0.01). Glucose and insulin tolerance test revealed that diet-induced severe insulin resistance was clearly improved after Akt1 activation in skeletal muscle. When Akt1-induced muscle growth was blocked by treatment with rapamycin, the fat mass regression effect was not observed. In conclusion, Akt1-mediated skeletal muscle growth, independent of food consumption or physical activity, can regress adiposity and obesity related insulin resistance.
Outbreak of salmonellosis after a wedding party, Bavaria, Germany, summer 2010: the importance of implementing food safety concepts
Authors: B von Wissmann, C Klinc, R Schulze, A Wolf, H Schreiner, W Rabsch, R Prager, W Hautmann
Journal: Eurosurveillance (2012)

Binary file ES_Abstracts_Final_ECDC.txt matches
Abstract 20006: Surgical Strategy of Aortic Coarctation Repair in Early Infancy Resulting in Physiologic Arm and Leg Blood Pressures at Intermediate-Term Follow-up
Authors: Michael Swartz, Matthew Schiralli, Jill Cholette, Cecilia Meagher, Joseph Orie, Nadar Attalah-Yunes, Rae-Ellen Kavey, Fransisco Gensini, George Alfieris
Journal: Circulation (2010)

Objectives:  The goal of aortic coarctation repair is to produce laminar aortic blood flow resulting in a negative or absent arm:leg BP gradient. Despite satisfactory surgical results, arch hypoplasia associated with coarctation in early infancy is frequently associated with residual arch obstruction and systemic hypertension.   Methods:  We use a surgical strategy to select candidates for sternotomy vs. thoracotomy in order to create an anastomosis with a diameter as large as both the adjacent proximal and distal aorta, in a tension-free setting. In all cases, we use a radically extended end to end anastomosis after aggressive aortic mobilization. Sternotomy is chosen when there is significant transverse arch hypoplasia (proximal transverse arch ≤ diameter of left carotid), the presence of a bovine arch or the presence of a co-existing intracardiac lesion requiring repair. Thoracotomy is used in all other cases. Left subclavian artery sacrifice is often necessary with either approach. Since January of 2000, all pts under 6 months of age with coarctation were repaired using this strategy. All patient data was evaluated for normal distribution, and evaluated using t-tests.   Results:  From 2000-2008, 95 consecutive patients were repaired (35-sternotomy 60-thoracotomy). The median age at repair was 15±49 days. There was no in-hospital mortality. At a follow up of 50 ±23 months, mean systolic BP was 94±10 mmHg, and 84% of pts had either a negative or absent arm:leg BP gradient. Mean arm:leg BP gradient was not statistically different between groups (−8.5±15 sternotomy and −7.0 ±10 mmHg thoracotomy, p=0.7). With echo Doppler, 96% of patients demonstrated normal early diastolic reversal of blood flow in the descending thoracic aorta. Mean maximum Doppler velocity in the descending thoracic aorta was 1.9± 0.4 for sternotomy and 2.0 ±0.4 m/s for thoracotomy. Two thoracotomy patients (2.1%) required re-intervention because of abnormal arm:leg BP gradients > +20 mmHg.   Conclusions:  For aortic coarctation during infancy, a strategy designed to directly address aortic arch hypoplasia results in excellent intermediate term results with both near normal aortic blood flow velocities by Doppler and arm:leg BP gradients.
Abstract 2534: Real-time Endobronchial Ultrasound Is A Safe Alternative To Angio-CT In The Diagnosis Of Central Pulmonary Embolism
Authors: Josef Aumiller, Norbert Schleucher, Mark Krasnik, Felix Herth, Ralf Eberhardt, Thoraxklinik Heidelberg
Journal: Circulation (2007)

Introduction: Life threatening central pulmonary embolism (PE) is defined as thrombotic occlusion of the main pulmonary trunk or of main or lobar pulmonary artery. These vessels accompany the trachea, the main and lobar bronchi at a distance of less than 5 mm. Chest CT enhanced with iv contrast (Angio-CT) has become the gold standard to evaluate suspected, central PE. Here we report imaging of central PE using real-time endobronchial ultrasound (rtEBUS). Hypothesis: rtEBUS is equivalent to Angio-CT in diagnosing central PE. Methods: In 20 consecutive patients we compared the visualization of central PE by rtEBUS versus Angio-CT using an Olympus ultrasonic bronchoscope BFUC 160F. Results: PE was discovered fortuitously via rtEBUS in 7 patients, who were submitted for rtEBUS for hilar and mediastinal lymph nodes in staging of lung cancer. In all 7 patients PE was verified by Angio-CT. In 12 patients with primary documented PE by Angio-CT we were able to visualize all central pulmonary emboli by rtEBUS. Two additional patients were explored for PE by rtEBUS as initial diagnostic procedure because of massive obesity and renal failure. The first diagnosis was confirmed by autopsy, the second by Angio-CT after 4 days with normalized renal function. In all patients we could visualize the pulmonary trunk, both main pulmonary arteries and the lobar arteries at a length of 10 mm by rtEBUS. Duration of the rtEBUS procedure was 5 +/-2 minutes. There were no rtEBUS related complications. All central PE were confirmed by Angio-CT, demonstrating a valid congruence. Conclusions: This is the first study to demonstrate that rtEBUS of central pulmonary arteries is a reliable and safe tool for the diagnosis of central PE. Especially in patients with renal impairment, anaphylaxis to intravenous contrast, pregnancy, cardiogenic shock or signs of acute right ventricular failure rt EBUS may be a valuable alternative to Angio-CT.
Abstract 3953: Type 2 Diabetes and the Coronary Angiographic State are Mutually Independent Predictors of Future Vascular Events Among Angiographied Coronary Patients
Authors: Christoph H Saely, Philipp Rein, Fabian Schmid, Lorena Koch, Stefan Aczel, Thomas Marte, Peter Langer, Guenter Hoefle, Heinz Drexel
Journal: Circulation (2006)
The Effects of Topical Corticosteroids and Plasmin Inhibitors on Refractive Outcome, Haze, and Visual Performance after Photorefractive Keratectomy
Authors: David P.S. O'Brart, Chris P. Lohmann, Gregory Klonos, Melanie C. Corbett, William S.T. Pollock, Malcolm G. Kerr-Muir, John Marshall
Journal: Ophthalmology (1994)
Prevalence, burden, and treatment of insomnia in primary care
Authors: G E Simon, M VonKorff
Journal: American Journal of Psychiatry (1997)

The prevalence, burden, and management of insomnia among primary care patients were evaluated.Consecutive patients aged 18 to 65 years in primary care clinics of a staff-model health maintenance organization (N = 1,962) were screened with the 12-item General Health Questionnaire. A stratified random sample (N = 373) completed face-to-face diagnostic assessments including the Composite International Diagnostic Interview, a brief self-rated disability questionnaire (Brief Disability Questionnaire), and the interviewer-rated Social Disability Schedule. A telephone follow-up survey was completed 3 months later. Use of psychotropic drugs, use of mental health services, and direct health care costs were assessed by using the health plan's automated data systems.Approximately 10% of the primary care patients reported major current insomnia (e.g., taking at least 2 hours to fall asleep nearly every night). Current insomnia was associated with significantly greater functional impairment (according to both Brief Disability Questionnaire and Social Disability Schedule), more days of disability due to health problems, and greater general medical service utilization. While insomnia was associated with depressive disorder and chronic medical illness, adjustment for these factors only partially accounted for the association of insomnia with disability and with health care utilization. Of the patients with current insomnia, 28% received any psychotropic drug; 14% received benzodiazepines and 19% received antidepressants.Insomnia among primary care patients is associated with greater functional impairment, lost productivity, and excess health care utilization.
The Effect of Losartan Versus Atenolol on Cardiovascular Morbidity and Mortality in Patients With Hypertension Taking Aspirin
Authors: Eigil Fossum, Andreas Moan, Sverre E. Kjeldsen, Richard B. Devereux, Stevo Julius, Steven M. Snapinn, Jonathan M. Edelman, Ulf de Faire, Frej Fyhrquist, Hans Ibsen, Krister Kristianson, Ole Lederballe-Pedersen, Lars H. Lindholm, Markku S. Nieminen, Per Omvik, Suzanne Oparil, Hans Wedel, Björn Dahlöf
Journal: Journal of the American College of Cardiology (2005)
Abstract 1416: Family Partnership and Education Interventions Reduce Dietary Sodium Intake by Patients With Heart Failure
Authors: Sandra B Dunbar, Patricia C Clark, Andrew L Smith, Carolyn M Reilly, Rebecca Gary, Frances McCarty, Judith Robinson, Nadine Kaslow
Journal: Circulation (2009)

Purpose: Lowering dietary sodium by persons with heart failure (HF) is difficult and most often occurs within the home and family context. We hypothesized that a HF family partnership intervention ...
Microsponge based drug delivery system for augmented gastroparesis therapy: Formulation development and evaluation
Authors: Riyaz Ali M. Osmani, Nagesh H. Aloorkar, Bharati U. Thaware, Parthasarathi K. Kulkarni, Afrasim Moin, Umme Hani, Atul Srivastava, Rohit R. Bhosale
Journal: Asian Journal of Pharmaceutical Sciences (2015)

The intention behind the present work was to develop a microsponge based novel dosage form for sustained delivery of domperidone. Quasi-emulsion solvent diffusion method was employed using Eudragit RS-100 with various drug–polymer ratios for the preparation of microsponges. For optimization purposes, several factors which affect microparticles' physical properties were investigated. Characterization techniques followed for the formed microsponges were DSC, FTIR, SEM, XRD and particle size analysis, along with morphology, drug loading and in vitro drug release. It was found that there were no chemical interactions between drugs and polymers used as per DSC and FTIR results. The drug–polymer ratio showed remarkable impact on drug content, encapsulation efficiency and particle size. SEM micrographs revealed that microsponges were spherical in shape with porous surface, and had 104 ± 0.22 µm mean particle size. The microsponges were then loaded in capsules followed by in vitro drug release study; which depicted that microsponges with drug–polymer ratio of 1:2 were more proficient to give extended drug release of 76.38% at the end of 8 h, superior in contrast to conventional marketed formulation Domstal®, which got exhausted incredibly earlier by releasing 82.57% drug at the end of ½ h only. Hence, the developed microsponge based formulation of domperidone would be an expectant, promising substitute to conventional therapy of gastroparesis, emesis and alike gastric ailments.
Abstract 6073: Dexrazoxane Cardioprotection in Doxorubicin-Treated Children with Acute Lymphoblastic Leukemia: Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocol 95–01 Randomized Controlled Trial
Authors: Steven E Lipshultz, Rebecca E Scully, Stuart R Lipsitz, Stephen E Sallan, Lewis B Silverman, Tracie L Miller, Elly V Barry, Barbara L Asselin, Uma Athale, Luis A Clavell, Eric Larsen, Albert Moghrabi, Yvan Samson, Marshall A Schorin, E. John Orav, Steven D Colan
Journal: Circulation (2008)

Background: Doxorubicin (DOX) chemotherapy injures myocardial cells, leading to progressive cardiac dysfunction. Dexrazoxane (DZR), a free-radical scavenger, reduced troponin T (cTnT) elevation during therapy in children with acute lymphoblastic leukemia (ALL) on Dana-Farber Cancer Institute (DFCI) Protocol 95– 01. The long-term cardiac benefits of DZR are not yet known. Methods: We centrally remeasured echocardiograms from childhood ALL survivors who were randomly assigned to DOX (n =64; 30 mg/m 2 /dose for 10 doses) with or without DZR (n =58; 300 mg/m 2 /dose) during DFCI Protocol 95– 01. Results: Demographics and follow-up were similar in both arms (median f/u years: DOX 4.0 vs. DZR/DOX 3.7). Mean left ventricular (LV) end-systolic dimension was significantly abnormal for DOX vs. DZR/DOX at 3 years (mean Z-score: DOX 0.637 vs. DZR/DOX −0.0005, P=0.0164) and progressed at 3.5 years (0.800 vs. −0.006, P=0.0028) and 4 years (1.01 vs. 0.005, P=0.0013). DOX-group mean LV end-diastolic (ED) dimension was significantly dilated at 3.5 years (mean Z-score: DOX 0.223 vs. DZR/DOX −0.424, P=0.022) and 4 years (0.428 vs. −0.456, P=0.004). With 3.5 years follow-up, a number of non-significant trends showed DZR/DOX echo measures to be more normal: LV fractional shortening Z-score (DOX −2.092 vs. DZR/DOX −1.00); LV mass Z-score (−0.672 vs. −0.537); LVED posterior wall thickness Z-score (LVEDPWTz; −0.596 vs. −0.395). For DZR/DOX-patients, cTnT elevation (defined as &gt;0.01 ng/ml) during DOX treatment correlated with thinner LVED posterior wall 3.5 years post treatment (mean LVEDPWTz: cTnT− =−0.011 vs. cTnT+= −1.200, P=0.0352). Conclusions: DZR is protective against late DOX cardiotoxicity with smaller LV dimensions, consistent with less LV remodeling. LV function, thickness, and mass trended to more normal among children who received DZR and all parameters trended toward a greater DZR effect over time. Further, cTnT elevation during therapy predicted late LV wall thinning. Table 1: Post-treatment Mean Differences in Dimension Z-Scores